Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03611738 | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | active not recruiting | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04380636 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | active not recruiting | Phase 3 | 870 | Merck Sharp & Dohme LLCINDUSTRY | 26 | May 15, 2026 |
| clinicaltrials |
| NCT04526691 | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | active not recruiting | Phase 1 | 145 | Daiichi SankyoINDUSTRY | 5 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT05653752 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | active not recruiting | Phase 1 | 80 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT06043947 | Survival Monitoring in Russian Cancer Registries(SURVIMON) | active not recruiting | — | 100,000 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06606847 | A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)(LADOGA) | active not recruiting | Phase 2 | 30 | AstraZenecaINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT03807778 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 53 | TakedaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT04204499 | Analysis of Screen-detected Lung Cancers' Genomic Traits(ASCENT) | active not recruiting | — | 526 | University College, LondonOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06946797 | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate-1533) | active not recruiting | Phase 2 | 76 | Bristol-Myers SquibbINDUSTRY | 9 | May 14, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05353439 | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT02998567 | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab(HyPeR) | active not recruiting | Phase 1 | 60 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | May 12, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03819465 | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC(MAGELLAN) | active not recruiting | Phase 1 | 175 | AstraZenecaINDUSTRY | 9 | May 12, 2026 | clinicaltrials |
| NCT07485179 | Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases | active not recruiting | — | 770 | Brigham and Women's HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581379 | Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations(PLuS2) | active not recruiting | — | 1,826 | University of FloridaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04716946 | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | active not recruiting | Phase 2 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04940936 | Shared Decision Making on Radiation Dose for Lung Malignancies | active not recruiting | N/A | 40 | Vejle HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05615142 | Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. | active not recruiting | Phase 1 | 9 | Sichuan UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03202940 | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | active not recruiting | Phase 1 / Phase 2 | 16 | Massachusetts General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05092412 | Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC | active not recruiting | Phase 2 | 30 | You LuOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05870319 | A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | active not recruiting | Phase 3 | 376 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06020443 | Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France.(DECANPHAR) | active not recruiting | N/A | 126 | Groupe Hospitalier de la Region de Mulhouse et Sud AlsaceOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06351085 | Enhancing Lung Cancer Screening Through Human-Centered Intervention(ELFE) | active not recruiting | N/A | 2,869 | University of California, DavisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06448312 | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 406 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07485166 | Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases | active not recruiting | — | 810 | Brigham and Women's HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)(EVOKE-01) | active not recruiting | Phase 3 | 603 | Gilead SciencesINDUSTRY | 20 | May 7, 2026 | clinicaltrials |
| NCT06014762 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | active not recruiting | Phase 1 | 120 | Poseida Therapeutics, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06051136 | Early Versus Delayed Rehabilitation Intervention in Patients With Lung Cancer(OVER-CRF) | active not recruiting | N/A | 31 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 7, 2026 | clinicaltrials |
| NCT02417662 | Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer(SARON) | active not recruiting | N/A | 140 | University College, LondonOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02434809 | Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies | active not recruiting | N/A | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT04734145 | Using e-Nose Technology to Identify Early Lung Cancer | active not recruiting | — | 119 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05557591 | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | active not recruiting | Phase 2 | 51 | Regeneron PharmaceuticalsINDUSTRY | 7 | May 6, 2026 | clinicaltrials |
| NCT03181256 | Early Detection of Lung Cancer | active not recruiting | — | 45 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04430725 | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study | active not recruiting | — | 74 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04564157 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy(NADIM-ADJUVANT) | active not recruiting | Phase 3 | 210 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05012254 | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases(NIVIPI-Brain) | active not recruiting | Phase 2 | 71 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05138900 | A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer | active not recruiting | N/A | 30 | Roswell Park Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05684276 | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors(DUMAS) | active not recruiting | Phase 2 | 22 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06268613 | A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy | active not recruiting | Phase 1 | 163 | Samsung Bioepis Co., Ltd.INDUSTRY | 4 | May 5, 2026 | clinicaltrials |
| NCT06489678 | Benefit of Cone-beam CT and Robotic-Assisted Bronchoscopy During Bronchoscopy | active not recruiting | N/A | 300 | University of ZurichOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT01888601 | TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)(TRACERx) | active not recruiting | — | 814 | University College, LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05491811 | Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation(EAGLE) | active not recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05195632 | Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer(OCEANII) | active not recruiting | Phase 2 | 63 | Pierre Fabre MedicamentINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT03838159 | NADIM II: Neo-Adjuvant Immunotherapy(NADIMII) | active not recruiting | Phase 2 | 90 | Fundación GECPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials